| 11/01/23 | 13:00:01 | 11 Jan 2023 | | Airsupra (PT027) approved in US for asthma | RNS |
| 09/01/23 | 07:00:02 | 9 Jan 2023 | | AstraZeneca acquire CinCor for cardiorenal asset | RNS |
| 03/01/23 | 15:00:01 | 3 Jan 2023 | | Total Voting Rights | RNS |
| 30/12/22 | 11:00:01 | 30 Dec 2022 | | Director/PDMR Shareholding | RNS |
| 28/12/22 | 07:05:06 | 28 Dec 2022 | | Calquence Japan approval for treatment-naïve CLL | RNS |
| 28/12/22 | 07:00:08 | 28 Dec 2022 | | Imfinzi, Imjudo approved in Japan for 3 cancers | RNS |
| 21/12/22 | 07:05:00 | 21 Dec 2022 | | Lynparza approved in EU for prostate cancer | RNS |
| 21/12/22 | 07:00:05 | 21 Dec 2022 | | Imfinzi approved in EU for biliary tract cancer | RNS |
| 19/12/22 | 07:20:03 | 19 Dec 2022 | | Enhertu recommended for EU approval in HER2-low BC | RNS |
| 19/12/22 | 07:15:04 | 19 Dec 2022 | | Enhertu approved in EU for gastric cancer | RNS |
| 19/12/22 | 07:10:04 | 19 Dec 2022 | | Imfinzi + Imjudo recommended for approvals in EU | RNS |
| 19/12/22 | 07:05:03 | 19 Dec 2022 | | Update on Imfinzi PEARL trial | RNS |
| 19/12/22 | 07:00:06 | 19 Dec 2022 | | Forxiga CHMP opinion for symptomatic chronic HF | RNS |
| 15/12/22 | 07:00:02 | 15 Dec 2022 | | Update on US review of Lynparza PROpel sNDA | RNS |
| 08/12/22 | 13:30:01 | 8 Dec 2022 | | Capivasertib PFS in HR-positive breast cancer | RNS |
| 01/12/22 | 15:00:04 | 1 Dec 2022 | | Block listing Interim Review | RNS |
| 01/12/22 | 15:00:04 | 1 Dec 2022 | | Total Voting Rights | RNS |
| 30/11/22 | 07:05:01 | 30 Nov 2022 | | AstraZeneca announces sale of West Chester site | RNS |
| 29/11/22 | 07:00:06 | 29 Nov 2022 | | AstraZeneca to acquire Neogene Therapeutics | RNS |
| 23/11/22 | 15:30:01 | 23 Nov 2022 | | Director/PDMR Shareholding | RNS |
| 14/11/22 | 07:10:05 | 14 Nov 2022 | | Enhertu recommended for EU approval in gastric | RNS |
| 14/11/22 | 07:05:05 | 14 Nov 2022 | | Imfinzi recommended for approval in the EU for BTC | RNS |
| 14/11/22 | 07:00:06 | 14 Nov 2022 | | Lynparza combo recommended in the EU for mCRPC | RNS |
| 11/11/22 | 07:00:06 | 11 Nov 2022 | | Imfinzi + Imjudo approved in US for lung cancer | RNS |
| 10/11/22 | 07:00:06 | 10 Nov 2022 | | YTD and Q3 2022 Results | RNS |
| 09/11/22 | 07:00:08 | 9 Nov 2022 | | FDA Advisory Committee recommends PT027 in asthma | RNS |
| 04/11/22 | 07:00:03 | 4 Nov 2022 | | Beyfortus (nirsevimab) approved in EU | RNS |
| 01/11/22 | 15:00:02 | 1 Nov 2022 | | Total Voting Rights | RNS |
| 26/10/22 | 07:00:05 | 26 Oct 2022 | | Capivasertib Phase III trial met primary endpoints | RNS |
| 25/10/22 | 07:00:06 | 25 Oct 2022 | | Update on MESSINA Phase III trial | RNS |
| 24/10/22 | 07:00:09 | 24 Oct 2022 | | Imfinzi + Imjudo approved in advanced liver cancer | RNS |
| 03/10/22 | 15:00:01 | 3 Oct 2022 | | Total Voting Rights | RNS |
| 30/09/22 | 10:30:07 | 30 Sept 2022 | | Board Committee Changes | RNS |
| 27/09/22 | 07:05:05 | 27 Sept 2022 | | Koselugo approved in Japan for NF1 | RNS |
| 27/09/22 | 07:00:07 | 27 Sept 2022 | | Tezspire approved in Japan for severe asthma | RNS |
| 23/09/22 | 07:00:08 | 23 Sept 2022 | | Ultomiris approved in EU for gMG | RNS |
| 22/09/22 | 07:00:14 | 22 Sept 2022 | | Lynparza approved in China for ovarian cancer | RNS |
| 21/09/22 | 07:00:06 | 21 Sept 2022 | | Tezspire approved in the EU for severe asthma | RNS |
| 20/09/22 | 07:00:13 | 20 Sept 2022 | | Evusheld approved in EU for COVID-19 treatment | RNS |
| 16/09/22 | 07:10:01 | 16 Sept 2022 | | Danicopan Phase III trial met primary endpoint | RNS |
| 16/09/22 | 07:05:00 | 16 Sept 2022 | | Evusheld positive CHMP opinion in EU | RNS |
| 16/09/22 | 07:00:04 | 16 Sept 2022 | | Nirsevimab recommended for approval in EU by CHMP | RNS |
| 05/09/22 | 07:05:05 | 5 Sept 2022 | | Forxiga approved in China for CKD | RNS |
| 05/09/22 | 07:00:07 | 5 Sept 2022 | | Imfinzi approved in US for biliary tract cancer | RNS |
| 01/09/22 | 15:00:04 | 1 Sept 2022 | | Total Voting Rights | RNS |
| 30/08/22 | 13:00:01 | 30 Aug 2022 | | Evusheld approved for COVID-19 in Japan | RNS |
| 30/08/22 | 07:01:04 | 30 Aug 2022 | | Farxiga shows CV mortality benefit across EF range | RNS |
| 30/08/22 | 07:00:13 | 30 Aug 2022 | | Farxiga reduced risk of CV death or worsening HF | RNS |
| 25/08/22 | 07:10:01 | 25 Aug 2022 | | Ultomiris approved in Japan for gMG | RNS |
| 25/08/22 | 07:05:00 | 25 Aug 2022 | | Tagrisso approved in Japan for early lung cancer | RNS |
